All In Biotech

NDA 204369 · Bayer Healthcare Pharms

Stivarga

Regorafenib · Oral

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 25, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Feb 25, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

310

38 Phase 3, 45 recruiting

FAERS reports

11,611

10,468 serious, 2,373 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 25, 2013 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · priority review OrphanLabelLetterReview
1 products under this application
  • STIVARGA · REGORAFENIB 40MG · TABLET, ORAL · Prescription · TE TBD

Clinical trials

Interventional ClinicalTrials.gov studies with "Regorafenib" as an intervention, any sponsor and status, largest first.

All 310 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,080
  • fatigue1,778
  • palmar-plantar erythrodysaesthesia syndrome1,446
  • diarrhoea1,427
  • decreased appetite1,097
  • death1,007
  • asthenia950
  • dysphonia825
  • nausea818
  • pain in extremity774
  • pyrexia757
  • hypertension700

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20112
2012119
2013928
2014810
2015886
2016653
20171,019
20181,150
2019980
2020962
2021956
2022870
2023770
2024694
2025567
2026245

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Stivarga (Regorafenib)

2024 spending

$96.4M

Beneficiaries

1,723

5,533 claims

Per beneficiary

$55,963

$266.34 per unit

View as table
YearSpending
2020$109,102,678
2021$110,788,615
2022$118,540,814
2023$111,001,740
2024$96,423,433

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 306 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.